Mirtazapina Doc Generici (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Doc Generici, is a NaSSA presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used within the antidepressant therapeutic class to address mood‑related disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (adjunct): helps alleviate the depressive phase when used with mood stabilisers. - Anxiety associated with depression: lessens anxiety symptoms that coexist with depressive illness.

Mirtazapine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Sedation or drowsiness: especially during the first weeks of therapy. - Increased appetite and weight gain: often reported in clinical practice. - Dry mouth: mild to moderate severity. - Constipation: may require dietary adjustments. - Dizziness: usually transient. - Peripheral edema: mild swelling of lower limbs.

Serious or Rare Side Effects: - Agranulocytosis: marked reduction in white blood cells. - Severe neutropenia: requires immediate medical attention. - Hepatic dysfunction: elevated liver enzymes. - Seizures: rare but reported. - Suicidal ideation: especially in younger adults. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: excreted in milk; consider alternatives. - Hepatic impairment: dose adjustment may be needed. - Renal impairment: monitor renal function and adjust if required. - Elderly patients: start at lower dose due to increased sensitivity. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Mirtazapine can interact with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin syndrome signs. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.